Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dih ydro-2H-indol-2-one-hydrochloride|
|Abstract:||The monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydr o-2H-indole-2-one hydrochloride has advantageous stability for formulation as a neuroleptic agent.|
|Inventor(s):||Allen; Douglas J. M. (New London, CT), Busch; Frank R. (Gales Ferry, CT), DiRoma; Sabeto A. (Uncasville, CT), Godek; Dennis M. (Glastonbury, CT)|
|Assignee:||Pfizer Inc. (New York, NY)|
Patent Claim Types:|
see list of patent claims
|Compound; Use; Composition; Process;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Austria||206422||<disabled in preview>|
|Austria||273976||<disabled in preview>|
|Australia||4600493||<disabled in preview>|
|This preview shows a limited data set|
Subscribe for full access, or try a Trial
Export unavailable in trial.
Subscribe for complete access.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.